Sound Bioventures
Venture capitalMalmö · Seed–Late Stage · 9 people tracked
Investment thesis
Sound Bioventures backs private biopharmaceutical companies that are about to enter or already in clinical stages, focusing on specialty therapeutic areas and the development of new medicines. The firm invests internationally across Europe and the USA, having originated as a Danish-Swedish partnership rooted in the Greater Copenhagen 'Medicon Valley' region. It positions itself as a straightforward, transparent and long-term-oriented co-investor that prioritizes doing what is right for its portfolio companies.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website & curated & public directories
What they invest in
from 15 of 22 portfolio companiesBiotech ×13Healthtech ×10Medical Devices ×5Media & Entertainment ×4AI & Machine Learning ×1Deep Tech ×1Fintech ×1Social ×1
HQs:Sweden×2United States×2Denmark×1France×1United Kingdom×1
Investments · 22 tracked
founders shown can be your intro pathAbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)Carole Guillonneau(Co-founder & Head of Research)inFrançois-Xavier Hubert(Co-founder, Past President & Board Member)
Co-investorsCriteria Bio VenturesNewton BiocapitalSambrinvestWallonie Entreprendre
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investors3B Future Health FundIndustrifondenNovo HoldingsPureos Bioventures
Arthex Biotech develops antisense RNA compounds to treat diseases with unmet medical needs.
AI & Machine LearningBiotechMedical Devices
Beatriz Llamusí(Chief Scientific Officer & Co-Founder)
Co-investorsBpifranceColumbus Venture PartnersHadean VenturesAdBio partnersInvivo Capital Partners
Teitur Trophics is a biotech company developing first-in-class cyclic peptides that target lysosomal, mitochondrial and pro-survival signaling pathways to preserve neuronal function.
BiotechDeep TechHealthtechAarhus, DK
Simon Mølgaard(Co-founder & CEO)Anders Dalby(Co-founder)Mathias Ollendorff(Co-founder)Simon Glerup(Co-founder)
Co-investorsIndustrifondenP53 InvestInnovestorSunstone Capital
Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment.
BiotechHealthtech
Co-investorsEpidarex CapitalOxford Science EnterprisesTaiho Ventures, LLCM Ventures
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter ReitsmaJohn Glasspool(Chief Executive Officer)
Co-investorsYsios CapitalBioGeneration VenturesEICEQT Life SciencesInkefUNIIQ+2 more
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.
BiotechHealthtechCambridge, US
Damia Tormo(President, CEO, Treasurer and Founder)Joe Suarez(Executive Officer)Maria Nichol(Executive Officer)Robert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)
BoardAndre Hoekema(Director)
Co-investorsAdvent Life SciencesColumbus Venture Partners
Clinical-stage biotech developing medicines through modulation of microRNAs; lead compound is ATX-01.
Co-investorsAdBio partnersHadean Ventures
Biotech Finances is a French-language news and analysis publication covering the biotech, pharma and medtech industries, focusing on financing, mergers and acquisitions, clinical developments and listed biotech valuations.
BiotechMedia & Entertainment
BioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals.
BiotechMedia & EntertainmentMedical Devices
BOOST Pharma is developing BT-101, a mesenchymal stem cell therapy for Osteogenesis Imperfecta (brittle bone disease) in children, based on research from Karolinska Institutet in Sweden.
BiotechHealthtechStockholm, SE
Lilian Walther Jallow(Co-founder & CDO)Cecilia Gotherstrom(Co-founder and member of SAB)Hans T. Schambye(Chief Executive Officer)Tony Hall(Chief Medical Officer)Louise Himmelstrup(Chief Regulatory Officer)
Co-investorsIndustrifonden
Born2Invest is an online financial news publication covering markets, investing, crowdfunding, biotechnology, and cryptocurrency for a general investor audience.
FintechMedia & Entertainment
Breye is a biotechnology company developing therapies for unmet medical needs, including danegaptide, an orally administered small molecule drug, and orally administered P2X7 receptor antagonists with anti-inflammatory and neuroprotective properties.
Biotech
Clinical-stage company developing ophthalmology therapies; lead program Danegaptide, an oral drug for diabetic retinopathy.
Preclinical-stage company developing next-generation gamma delta T cell engagers for solid and haematological malignancies.
Co-investorsPathway Bioventures
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway Bioventures
Hoama Group develops care and living communities for older adults, including specialized facilities for elderly deaf people using British Sign Language.
HealthtechMedia & EntertainmentSocialStaplehurst, GB
Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI).
BiotechHealthtechMedical DevicesSeattle, US
Jeff M. Sands, M.D.(Executive Officer)Jeff SandsJanet KleinJeff M. Sands(Chief Medical Officer & Founder)Janet D. Klein(Director of Biology & Founder)Rachael Hagan(President & Chief Executive Officer)
Co-investorsAdvance Venture Partners
Preclinical-stage company developing therapeutics for neurodegenerative diseases including Huntington's, Parkinson's and frontotemporal dementia.
Portfolio news
latest coverage across their companies
Bioworld · altss.com · Jun 3, 2026
Frequently asked questions
- How many investments has Sound Bioventures made?
- Sound Bioventures has 19 tracked investments.
- What stage does Sound Bioventures invest at?
- Sound Bioventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Sound Bioventures focus on?
- Sound Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Sound Bioventures located?
- Sound Bioventures is headquartered in Malmö, SE.
- Does Sound Bioventures lead rounds?
- Yes, Sound Bioventures leads investment rounds.
- Who does Sound Bioventures co-invest with?
- Sound Bioventures most often shares deals with DCVC (Data Collective), Epidarex Capital, Industrifonden, among 16 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.